Close Menu

NEW YORK – Women's health personalized medicine company DotLab said on Monday it has secured $10 million in Series A funding.

The San Francisco-based firm is combining noninvasive microRNA biomarkers with machine learning to develop a noninvasive test for endometriosis. In a statement, DotLab CEO Heather Bowerman said that the company will use the funds to "further clinical validation, expand market access, and continue to grow our team."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.